ArticlePloS one2025
Association of the platelet-to-high-density lipoprotein cholesterol ratio (PHR) with metabolic syndrome and metabolic overweight/obesity phenotypes: A study based on the Dryad database.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Association of platelet-to-HDL cholesterol ratio with hyperuricemia among Qatari adults: a national primary care study.Scientific reports · 2026Article
- Insights into Metabolically Healthy Obesity-A Narrative Review.Journal of clinical medicine · 2026Review
- Pediatric asthma: positive correlation between platelet-to-HDL-C ratio and blood eosinophil counts.Pediatric research · 2026Article
- Serum uric acid-to-HDL-C ratio as an independent predictor of metabolic syndrome in the elderly: diagnostic model optimization and inflammatory mechanism insights.BMC geriatrics · 2026Article
- Development and validation of a high-performance clinical predictive model for early identification of non-alcoholic fatty liver disease.Frontiers in physiology · 2026Article
- Association Between Platelet to High-Density Lipoprotein Cholesterol Ratio and Cardiometabolic Multimorbidity in Middle-Aged and Elderly Chinese Hypertensive Patients.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOverweight/obesity and metabolic syndrome (MetS) are major global public health challenges. The platelet-to-high-density lipoprotein cholesterol ratio (PHR) has emerged as a potential biomarker reflecting both inflammatory status and lipid metabolism; however, its association with MetS and metabolic overweight/obesity phenotypes is not well understood. The present study aims to investigate the association of the PHR with MetS and metabolic overweight/obesity phenotypes.
methodsWe derived data from the Dryad data repository. This retrospective study included 1,592 physical examination participants in Wuhan Union Hospital from 2020 to 2021. Based on BMI categories and metabolic status, we defined and distinguished four metabolic overweight/obesity phenotypes: metabolically healthy with normal weight (MHNW), metabolically unhealthy with normal weight (MUNW), metabolically healthy with overweight/obesity (MHO), and metabolically unhealthy with overweight/obesity (MUO). PHR was calculated as the ratio of platelets to HDL cholesterol. Logistic regression analysis was used to test the independent association between PHR with MetS and metabolic overweight/obesity phenotypes. In addition, we performed smooth curve fitting and subgroup analyses.
resultsLogistic regression analysis, after adjusting for covariates, indicated that each 10-unit increase in PHR was associated with elevated risks of MetS (OR = 1.29, 95% CI: 1.24-1.35). There was a significant positive association between PHR and the occurrence of both MHO (OR = 1.15, 95% CI: 1.11-1.19) and MUO (OR = 1.16, 95% CI: 1.12-1.20), while the association with MUNW remained unclear (P = 0.73). In addition, we found a nonlinear relationship between PHR and the incidence of MetS, MHO, and MUO.
conclusionPHR demonstrates strong associations with MetS, MHO, and MUO, indicating its potential utility as an early biomarker for metabolic dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.